SEC Filing Summary: Pieris Pharmaceuticals, Inc. (PIRS)
Business Context and Reporting Period
This Form 8-K was filed by Pieris Pharmaceuticals, Inc. on September 9, 2020. The registrant is a Nevada corporation with principal executive offices in Boston, MA, and its common stock trades on the Nasdaq Capital Market under the symbol "PIRS". The filing serves as a Regulation FD disclosure.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of an investor presentation rather than a financial statement.
Material Changes
No material financial changes versus a prior period are detailed in the text of this filing. The document solely references the attachment of an investor presentation.
Guidance, Outlook, and Risks
Item 7.01 discloses the attachment of the "September 2020 Investor Presentation" as Exhibit 99.1. The filing explicitly states that the information in this presentation is not deemed "filed" for any purpose and is not incorporated by reference into other SEC filings unless expressly stated. No specific guidance, risks, or management commentary are included in the body of this 8-K.
Key Facts for Investor Verification
- Verify the contents of Exhibit 99.1 (September 2020 Investor Presentation) for actual financial data and strategic updates.
- Note that the investor presentation is not legally "filed" or incorporated by reference into this 8-K.
- Confirm the company's status as an emerging growth company (indicated as unchecked in the form header).
- Review the Nasdaq Capital Market listing status for the common stock.